中慧生物-B（02627.HK）在上市首日表现强劲后，今日（8月12日）开盘后继续保持上涨势头。截至上午9:33，该股盘中大涨5.05%。
昨日（8月11日），中慧生物-B在港交所主板挂牌上市，首日收盘价报33.28港元，较发行价12.9港元大涨157.98%，市值超130亿港元。该公司在香港公开发售阶段获得超过19万人认购，超额认购倍数逾4000倍，认购金额超2000亿港元，成为今年港股"18A"生物科技板块的超购王。
市场分析人士指出，中慧生物-B上市后持续走强，反映了投资者对公司前景的看好。作为一家专注于创新疫苗研发、制造及商业化的企业，中慧生物拥有两款核心产品：已获批上市的四价流感病毒亚单位疫苗，以及正在研发中的冻干人用狂犬病疫苗。公司丰富的产品管线和在疫苗领域的技术优势，为其未来发展提供了有力支撑。
不过，分析师也提醒，由于目前仍处于交易日早期，投资者应密切关注该股后续走势。同时，考虑到疫苗行业的激烈竞争，中慧生物未来仍需在市场拓展和研发创新等方面持续发力，以巩固其市场地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.